Accurate measurement of clinical analytes in the presence of icterus, lipemia, and hemolysis has long been a challenge to clinical chemists [1] [2] [3] . Before being introduced into the clinical setting, every new method and analytical instrument is routinely tested for possible interference from these factors as well as from commonly used drugs. However, new drugs are continually being brought to market, yet testing for interference with routine laboratory methods is rarely included as part of the development of these drugs. An exception to this has been the development of stabilized hemoglobin-based oxygen carriers (HBOCs). 1 Because of the red color of these hemoglobin solutions, determination of the interference of HBOCs in routine laboratory tests has become a primary focus of the manufacturers of HBOCs, as evidenced by the formation of the Blood Substitutes Division of the AACC. Hospital-based clinical chemists are becoming sensitized to this iatrogenic cause of interference from hemoglobin now that several of these products are in late clinical trials throughout the US, Europe, and Canada.
The association between extracellular plasma hemoglobin and the development of renal damage is well known [4 -6] . In the early development of HBOCs, stroma-free hemoglobin preparations were associated with many of the physiological changes associated with hemolysis, including nephrotoxicity [7] . The proposed mechanism of renal injury involves the release of iron from hemoglobin and the subsequent promotion of free radical formation, lipid peroxidation, and renal dysfunction [8, 9] . The newer generation of HBOCs have been chemically modified to increase the molecular mass of the hemoglobin, thus minimizing renal clearance of hemoglobin while prolonging the life of the HBOC circulating in blood. Although renal damage from HBOCs is no longer a major safety concern, there remains the concern of a proteinoverload type of phenomenon, given the potentially large doses of HBOCs that could be administered to trauma or surgical patients or a possible increase in the filtered load of HBOCs in patients with compromised glomerular permeability. Thus, accurate laboratory assessment of renal function is needed in patients receiving HBOCs.
In this study, we compared the interference of oraffinose cross-linked hemoglobin (Hemolink TM ) with three methods for serum creatinine that are based on different assay principles. Hemolink is prepared from hemoglobin purified from outdated human erythrocytes that were previously tested and released for use in transfusions. The purified hemoglobin reacts with oraffinose, a polyaldehyde obtained through oxidation of the trisaccharide raffinose [10, 11] . The reductive alkylation process covalently cross-links amino groups within the 2,3-diphosphoglycerate binding pocket to form an irreversible linkage between two ␣␤ dimers (forming a 64-kDa tetramer). In addition, o-raffinose reacts with surface amino groups of the stabilized tetramers to create intermolecular linkages producing stable hemoglobin polymers (128 -600 kDa). The final Hemolink preparation is ϳ40% hemoglobin tetramer, the remaining ϳ60% consisting of hemoglobin polymers. In this study, our goal was to identify the method(s) with the least interference from Hemolink added to sera from both healthy individuals and individuals with increased concentrations of creatinine. The method(s) with the least interference would then be used in future clinical trials as part of the clinical assessment of renal function.
Materials and Methods
Creatinine assays. The three methods for creatinine we evaluated were the Boehringer Mannheim Corp. Test samples. Pools containing creatinine concentrations within the reference interval were prepared from serum samples collected from laboratory staff. Abnormal creatinine pools were prepared from clinical specimens tested in a routine hospital laboratory and found to have increased concentrations of creatinine. All samples were collected in compliance with institutional ethical standards. Samples were stored at 4°C upon arrival in the laboratory and tested within 7 days of collection.
Analysis of Interference.
Interference of Hemolink was calculated as the recovery of creatinine in the Hemolinksupplemented samples by use of the following formulas: absolute error ϭ C I Ϫ C 0 , and relative error ϭ C I /C 0 , where C I is the creatinine concentration in a sample containing Hemolink and C 0 is the creatinine concentration in the control sample without Hemolink [12] . Absolute and relative error were plotted as a function of the Hemolink concentration in each sample. Any interference observed was judged to be analytically significant when the relative interference exceeded the 95% confidence limits for each method.
Effect of Hemolink. Hemolink was prepared as a 100 g/L solution, measured as total hemoglobin with an IL-482 CO-oximeter (Instrumentation Laboratory). Each serum sample was diluted 4:1 (by vol) with various amounts of Hemolink and Lactated Ringer's Injection USP (LRS; excipient for Hemolink) to obtain approximate Hemolink concentrations of 0.0 (control sample), 1.25, 2.5, 5.0, 7.5, 10, 15, and 20 g/L. Two production lots of Hemolink were tested with serum pools containing normal and increased creatinine concentrations to determine lot-to-lot and serum pool-to-pool consistency of the potential interference. Samples were analyzed for creatinine by each of the methods described above.
Those methods showing no interference from Hemolink up to 20 g/L underwent additional studies to examine the effect of Hemolink up to 50 g/L. This time, normal and abnormal serum pools were diluted 1:1 (by vol) with various amounts of Hemolink and LRS to obtain approximate Hemolink concentrations of 0.0 (control sample), 10, 20, 30, 40, and 50 g/L. Interference was analyzed as described above.
Interference of Hemolink vs hemoglobin.
For all three methods, the interference from Hemolink was compared with that of a purified hemoglobin preparation, to determine whether the interference response was similar. Hemoglobin was prepared as an 80 g/L solution, as measured with an IL-482 CO-oximeter. Pooled sera containing normal or abnormal creatinine concentrations were diluted 4:1 (by vol) with hemoglobin and LRS to obtain approximate hemoglobin concentrations of 0.0 (control sample), 4, 8, 12, and 16 g/L. Samples were analyzed for creatinine by each of the methods described above, and results were compared with the interference of Hemolink in each creatinine method.
Results
Several serum pools were used to complete the study. Creatinine concentrations ranged from 44 to 97 mol/L in normal pools and from 147 to 548 mol/L in abnormal pools. The 95% confidence limits for each method were calculated from the precision data for routine qualitycontrol materials tested by each laboratory. The 95% confidence limits for the BMC/Hitachi 717 assay were 0.76 - Both the Synermed/Hitachi 717 method and the J&J/ Vitros 750 method showed no significant interference from Hemolink at concentrations as great as 20 g/L in the initial studies (Fig. 2) . The relative error observed for the Synermed/Hitachi 717 method varied from 0.89 to 1.12 in normal samples (n ϭ 6) and from 0.95 to 1.06 in abnormal samples (n ϭ 6). All results for normal and abnormal pools supplemented with 1.25 to 15 g/L of Hemolink were within the 95% confidence limits of the assay. For those samples supplemented with 20 g/L of Hemolink, the relative errors of 4 of the 6 samples with normal creatinine concentrations were slightly above the limit of 1.11 at relative errors of 1.12, 1.12, 1.14, and 1.22, whereas the results for the samples containing increased creatinine concentrations and Hemolink at 20 g/L were all within the 95% confidence limits of the assay. The relative error observed for the J&J/Vitros 750 method varied from 0.92 to 1.01 in normal samples (n ϭ 2) and from 0.97 to 1.00 in abnormal samples (n ϭ 4) and was within the 95% confidence limits of the assay.
When the Hemolink concentration was extended up to 50 g/L in later studies (Fig. 3) , the 95% confidence limits of the Synermed/Hitachi 717 method were exceeded at Hemolink concentrations Ն30 g/L in samples containing normal concentrations of creatinine (n ϭ 3) and were The difference in Hemolink interference observed between samples from different individuals or between serum pools, and between lots of Hemolink was well within the 95% confidence limits of the assay and was not considered significant.
We also compared the interferences from Hemolink and a purified preparation of hemoglobin. Interestingly, hemoglobin up to 16 g/L showed no interference with any of the three creatinine methods tested. Recovery of creatinine was within the 95% confidence limits for samples with both normal (n ϭ 3) and increased (n ϭ 3) creatinine concentrations-in contrast to the results for Hemolink, which showed a positive interference with the BMC/Hitachi 717 method.
Discussion
This study was performed in preparation for a Phase I safety trial in healthy volunteers, and was part of an extensive evaluation of routine laboratory methods for interference from Hemolink [13] . As mentioned previously, during the early development of HBOCs there were reports of renal toxicity following administration of HBOCs. In addition, administration of the current generation of HBOCs has been associated with increased iron in the renal tubules, the presence of red casts, and low concentrations of hemoglobin in the urine [14 -17] , indicating that small amounts of these stabilized HBOCs may be filtered through the kidney. Thus, in early clinical trials of Hemolink, a method for serum creatinine was required that would give accurate results for an unambiguous clinical evaluation of renal function.
For each of the methods compared in this study, Hemolink interference that exceeded the 95% confidence limits of each assay was considered to be analytically significant. We also considered the within-subject biological variability of serum creatinine in determining the importance of the observed interference on the clinical interpretation of the reported result. The serum creatinine measured in an individual subject can change by Ϯ10% by random variation alone [18] . When this variability is taken in context with the analytical variability of the assay, a difference of 14%-18% is required for detection of a significant (P Ͻ0.05) change between two serial creatinine results from the same subject [19 -21] . Therefore, in addition to identifying the potential analytical interference by Hemolink, we defined a limit of Ϯ14% from the control value as identifying an interference that would confound the clinical interpretation of serum creatinine measured in the presence of Hemolink.
The magnitude of the interference observed with the BMC/Hitachi 717 creatinine assay was considered unacceptable for reporting results in the presence of Hemolink. Interference exceeded both analytical and clinical limits at Hemolink concentrations Ն5.0 g/L in both normal and abnormal samples.
The J&J/Vitros 750 analyzer, however, showed no analytically or clinically significant interference from Hemolink (at concentrations up to 50 g/L). A trend was observed of decreasing recovery of creatinine with increasing concentration of Hemolink, but this trend did not attain clinical significance. The J&J method involves the application of the sample to a spreading layer on the surface of the slide, and the sample diffuses through to the reagent layer, where the indicator reaction takes place. Possibly, the spreading layer on the slide acts as a molecular sieve to restrict the passage of hemoglobin and other large molecules such as Hemolink. As a result, neither hemoglobin nor Hemolink would diffuse into the reagent slide layer, thereby minimizing the potential of hemoglobin-based interference with this method. In addition, the rate of formation of the indicator dye is monitored at 670 nm (10/92 package insert for creatinine single-slide method, no. MP2-49; Eastman Kodak Clinical Diagnostics Division). The absorbance of hemoglobin is minimal at this wavelength, virtually eliminating the potential for interference from this source.
The Synermed wet-chemistry method performed on the Hitachi 717 showed significant positive interference from Hemolink at concentrations Ͼ30 g/L in samples with normal creatinine concentrations. There was also a positive trend in the recovery of creatinine in abnormal samples, but this trend was not considered clinically significant for Hemolink concentrations up to 50 g/L. The Synermed method is similar to the BMC method, both being based on the kinetic Jaffe reaction and measuring the rate of formation of the Janovsky complex at 570 nm. The traditional kinetic Jaffe method was subject to interference from hemolysis because the absorbance of hemoglobin changes progressively during the measurement phase of the reaction because of the oxidation of hemoglobin. Current methods have addressed this interference by optimizing the reading times of the creatinine assay to minimize the interference from hemoglobin and other factors [22] -as can be seen by the lack of interference from purified hemoglobin at up to 16 g/L in both the BMC/Hitachi 717 and Synermed/Hitachi 717 assays. In contrast to the lack of hemoglobin interference with the BMC/Hitachi 717 creatinine assay, Hemolink caused a large positive interference with this method. The observed interference probably results from the more rapid rate of oxidation of the o-raffinose cross-linked hemoglobin than that of purified hemoglobin. The addition of a proprietary mixture of solvents and surfactants into the NaOH reagent of the Synermed/Hitachi 717 assay is thought to pre-oxidize the hemoglobin before the start of the kinetic measurement, thus stabilizing the background absorbance of the test sample during the reading phase and minimizing the hemoglobin interference (M. Arentz, Synermed Inc., personal communication). Our results show that this reagent system is also able to minimize the interference from Hemolink.
During the interference studies performed in preparation for the Phase I study, the question arose as to whether the interference from Hemolink in routine assays could be predicted by published data or manufacturers' data on the interference of hemoglobin or hemolysis. However, the comparison of the interference of Hemolink and purified hemoglobin in the three creatinine methods described here showed that the effect of Hemolink and hemoglobin on creatinine methods can differ substantially. In fact, one cannot assume that if a method has no interference from hemoglobin, then Hemolink, or other HBOCs, will also have no effect. Although the Synermed and J&J methods performed well in the presence of both hemoglobin and Hemolink, the BMC method performed poorly, showing significant positive interference from Hemolink but not from hemoglobin, as discussed above. Thus the published data on the effects of hemoglobin on clinical assays cannot be used to predict the effect of HBOCs.
In the routine clinical setting, these results indicate a need for each laboratory to investigate the effects of HBOCs on their own analytical systems. Interference results on one analytical system cannot be generalized to other reagents or instruments. From the differences in interference results observed between Hemolink and hemoglobin, it is also likely that interference results for one HBOC cannot be extended to other HBOCs. The issue is further complicated if the laboratory does not know when or which HBOC the patient has received, or whether in vitro or in vivo hemolysis has occurred. The long-term solution is for the reagent and instrument manufacturers to develop new systems that either eliminate the interference of HBOCs and hemolysis, or at least warn of the presence of chromogens that produce inaccurate results [3] . In the meantime, laboratories will need to assess the effect of these products on their analytical systems as the HBOCs are introduced into their hospitals, and, if necessary, introduce alternative methods (in-house or contract tests) to be able to report clinically meaningful results.
In conclusion, the BMC/Hitachi method showed significant interference from Hemolink and was considered unacceptable for evaluation of renal function in clinical trial subjects. The J&J/Vitros 750 dry-slide method showed no clinically significant interference from Hemolink up to 50 g/L. The Synermed method could, however, overestimate creatinine concentrations at the lower end of the reference range when Hemolink concentrations were Ͼ30 g/L, but showed no clinically significant interference from Hemolink up to 50 g/L at creatinine concentrations near or above the upper limit of the reference range. Thus both of these methods were deemed acceptable for use in the presence of plasma Hemolink concentrations as great as 50 g/L.
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